Demonstrating ophthalmic bioequivalence: A comprehensive PK/PD Study Framework under FDA and EMA guidance with MIDD as an enabling tool

Ophthalmic eye drops present one of the most demanding scenarios in bioequivalence (BE) science. Drug concentrations at the local site of action — the cornea, aqueous humor, and uveal tissues — are largely inaccessible through conventional plasma-based pharmacokinetic (PK) sampling. In response, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have developed product-specific, graduated regulatory frameworks that deploy three classes of in vivo evidence for ophthalmic BE: aqueous humor PK studies, pharmacodynamic (PD) endpoint studies using intraocular pressure (IOP) or clinical outcome measures, and plasma PK studies for systemically absorbed drugs. These approaches are operationalized through the FDA’s Product-Specific Guidance (PSG) system and the EMA’s product-specific bioequivalence guideline (PSBGL) framework. This article presents a rigorous, guideline-anchored review of how PK and PD study methodologies are applied to demonstrate ophthalmic BE, using multiple drug class examples including prostaglandin analogues (latanoprost), alpha-2 agonists (brimonidine), corticosteroids (loteprednol etabonate, prednisolone acetate), and anti-infectives. We further describe how Model-Informed Drug Development (MIDD) — particularly physiologically-based ocular PK (PBOPK) modeling and population PK analysis — functions as a scientifically enabling tool within, not instead of, the existing regulatory BE framework. An optimal study design and regulatory submission strategy aligned with current FDA and EMA requirements is proposed, with explicit guidance on when PK versus PD endpoints are appropriate, how BE statistical criteria are applied in each context, and what MIDD can contribute at each stage.